Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
Background
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Items 301–400 of 1,014
Targeting Cancer Cell Mitochondria as a Therapeutic Approach
Wen, S., Zhu, D., & Huang, P. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.190 · Cited by 200
“For example, phenethyl isothiocyanate, a natural product found in cruciferous vegetables, has been shown to have a potent anticancer activity by disabling the glutathione (GSH) antioxidant system, resulting in severe ROS accumulation in cancer cells and consequently oxidative damage and cell death [1,2].”
BackgroundSelf-citationNowak, A., Paliwoda, A., & Błasiak, J. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1494539 · Cited by 199
“Antioxidant properties of these strains can be also considered in cancer treatment as some cancer therapies are based on a specific ROS overproduction in cancer cells (Trachootham, Alexandre, and Huang 2009).”
BackgroundDNA damage by lipid peroxidation products: Implications in cancer, inflammation and autoimmunity
Gentile, F., Arcaro, A., Pizzimenti, S., Daga, M., Cetrangolo, G. P., Dianzani, C., Lepore, A., Graf, M., Ames, P. R. J., & Barrera, G. (2017) · AIMS Genetics · doi:10.3934/genet.2017.2.103 · Cited by 205
“elevation of survival factors, such as apoptosis regulator Bcl-2 (BCL2) and induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1), and inhibition of cell death effectors, such as caspases [117,118].”
BackgroundJitschin, R., Hofmann, A. D., Bruns, H., Gießl, A., Bricks, J., Berger, J., Saul, D., Eckart, M. J., Mackensen, A., & Mougiakakos, D. (2014) · Blood · doi:10.1182/blood-2013-10-532200 · Cited by 201
“In fact, these seemingly contradictory findings could be explained by a compensatory adaptation of CLL cells to persistent oxidative stress.(4) Mitochondrial ROS levels and mitochondrial biogenesis in”
BackgroundLu, J., Zhang, H., Li, S., Guo, S., Shen, L., Zhou, T., Zhong, H., Wu, L., Meng, Q., & Zhang, Y. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b03512 · Cited by 192
Liu, J., Yuan, Y., Cheng, Y., Fu, D., Chen, Z., Wang, Y., Zhang, L., Yao, C., Shi, L., Li, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11856 · Cited by 202
Redox implications of AMPK-mediated signal transduction beyond energetic clues
Cardaci, S., Filomeni, G., & Ciriolo, M. R. (2012) · Journal of Cell Science · doi:10.1242/jcs.095216 · Cited by 197
Wang, L., Sun, Q., Wang, X., Wen, T., Yin, J.-J., Wang, P., Bai, R., Zhang, X.-Q., Zhang, L.-H., Lu, A.-H., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511560b · Cited by 204
Oxidation-responsive polymers for biomedical applications
Song, C.-C., Du, F.-S., & Li, Z.-C. (2014) · J. Mater. Chem. B · doi:10.1039/c3tb21725f · Cited by 203
Yin, W., Ke, W., Chen, W., Xi, L., Zhou, Q., Mukerabigwi, J. F., & Ge, Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.032 · Cited by 202
In vivo self-bio-imaging of tumors through in situ biosynthesized fluorescent gold nanoclusters
Wang, J., Zhang, G., Li, Q., Jiang, H., Liu, C., Amatore, C., & Wang, X. (2013) · Scientific Reports · doi:10.1038/srep01157 · Cited by 202
Photo-triggered antibacterial and anticancer activities of zinc oxide nanoparticles
Sivakumar, P., Lee, M., Kim, Y.-S., & Shim, M. S. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00948a · Cited by 197
Pu, H.-L., Chiang, W.-L., Maiti, B., Liao, Z.-X., Ho, Y.-C., Shim, M. S., Chuang, E.-Y., Xia, Y., & Sung, H.-W. (2014) · ACS Nano · doi:10.1021/nn4058787 · Cited by 196
Dong, L.-F., Jameson, V. J. A., Tilly, D., Cerny, J., Mahdavian, E., Marín-Hernández, A., Hernández-Esquivel, L., Rodríguez-Enríquez, S., Stursa, J., Witting, P. K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186643 · Cited by 200
Cancer Metabolism and the Evasion of Apoptotic Cell Death
Sharma, A., Boise, L., & Shanmugam, M. (2019) · Cancers · doi:10.3390/cancers11081144 · Cited by 185
Ratovitski, E. A., Cheng, X., Yan, D., Sherman, J. H., Canady, J., Trink, B., & Keidar, M. (2014) · Plasma Processes and Polymers · doi:10.1002/ppap.201400071 · Cited by 199
CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer
Swaminathan, S. K., Roger, E., Toti, U., Niu, L., Ohlfest, J. R., & Panyam, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.014 · Cited by 196
Review of Functionalized Nanomaterials for Photothermal Therapy of Cancers
Bian, W., Wang, Y., Pan, Z., Chen, N., Li, X., Wong, W.-L., Liu, X., He, Y., Zhang, K., & Lu, Y.-J. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c01903 · Cited by 194
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 188
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. A., Ortiz-Sánchez, E., & García-Carrancá, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 180
Yang, N., Gong, F., Liu, B., Hao, Y., Chao, Y., Lei, H., Yang, X., Gong, Y., Wang, X., Liu, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29938-6 · Cited by 196
Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma
LaGory, E. L., Wu, C., Taniguchi, C. M., Ding, C.-K. C., Chi, J.-T., von Eyben, R., Scott, D. A., Richardson, A. D., & Giaccia, A. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.006 · Cited by 193
“Malignant cells often exhibit elevated steady state levels of ROS rendering them exquisitely sensitive to further increases in ROS production from the mitochondria (Trachootham et al., 2009).”
BackgroundTeymouri, M., Pirro, M., Johnston, T. P., & Sahebkar, A. (2017) · BioFactors · doi:10.1002/biof.1344 · Cited by 192
“They concluded that increased ROS stress beyond a threshold could induce ER stress-mediated apoptosis in cancer cells, while lower levels of ROS generation though the same pathway might result in ER homeostasis, resulting in cancer cell survival under moderate stress like hypoxia, and the evasion of normal cells from…”
BackgroundWang, G., Zhou, Z., Zhao, Z., Li, Q., Wu, Y., Yan, S., Shen, Y., & Huang, P. (2020) · ACS Nano · doi:10.1021/acsnano.0c00974 · Cited by 193
Self-citationZambonino, M. C., Quizhpe, E. M., Mouheb, L., Rahman, A., Agathos, S. N., & Dahoumane, S. A. (2023) · Nanomaterials · doi:10.3390/nano13030424 · Cited by 184
Kong, X., Thimmulappa, R., Kombairaju, P., & Biswal, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902315 · Cited by 191
“GSH is the major ROS-scavenging system in cells (28).”
5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry
Kaminskyy, D., Kryshchyshyn, A., & Lesyk, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.031 · Cited by 184
Enzymatic Cleavage of Branched Peptides for Targeting Mitochondria
He, H., Wang, J., Wang, H., Zhou, N., Yang, D., Green, D. R., & Xu, B. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11582 · Cited by 195
Targeting Bacterial Central Metabolism for Drug Development
Murima, P., McKinney, J. D., & Pethe, K. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.020 · Cited by 189
“…central metabolism are being developed within the pharmaceutical industry for many different applications such as cancer, diabetes, and other metabolic disorders (Cabello et al., 2007; Hawser et al., 2006; Pelicano et al., 2004; Schumacker, 2006; Trachootham et al., 2009; Vander Heiden, 2011).”
BackgroundInfluentialXc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism
Ma, M.-Z., Chen, G., Wang, P., Lu, W.-H., Zhu, C.-F., Song, M., Yang, J., Wen, S., Xu, R.-H., Hu, Y., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.031 · Cited by 186
“For instance, glutamylcysteine synthetase (γ-GCS) is the rate-limiting enzyme for GSH synthesis and important redox modulating enzymes, including peroxidases, peroxiredoxins and thiol reductases, which rely on the pool of reduced GSH in the cell as their source of reducing equivalents [41].”
BackgroundSelf-citationDesign of a ratiometric two-photon probe for imaging of hypochlorous acid (HClO) in wounded tissues
Mao, Z., Ye, M., Hu, W., Ye, X., Wang, Y., Zhang, H., Li, C., & Liu, Z. (2018) · Chemical Science · doi:10.1039/c8sc01697f · Cited by 195
Hu, Q., Wei, W., Wu, D., Huang, F., Li, M., Li, W., Yin, J., Peng, Y., Lu, Y., Zhao, Q., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.810327 · Cited by 187
Wu, F., Du, Y., Yang, J., Shao, B., Mi, Z., Yao, Y., Cui, Y., He, F., Zhang, Y., & Yang, P. (2022) · ACS Nano · doi:10.1021/acsnano.1c06777 · Cited by 191
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses
Peng, K., Zheng, Y., Xia, W., & Mao, Z.-W. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00757f · Cited by 188
Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets
Wang, Z., Li, Z., Ye, Y., Xie, L., & Li, W. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7891574 · Cited by 190
“[77, 78] 5-Aminoimidazole-4-carboxamide-1b-ribofuranoside (AICAR) Nrf2↑ Cons”
BackgroundRecent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy
Rao, N. V., Ko, H., Lee, J., & Park, J. H. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00110 · Cited by 184
“An excess of ROS can increase the risk of mutated cellular DNA, which is closely associated with progression of several cancer cell types (Trachootham et al., 2009).”
BackgroundEmerging role of NRF2 in ROS-mediated tumor chemoresistance
Xue, D., Zhou, X., & Qiu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110676 · Cited by 191
Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1
Xu, H., Zhao, H., Ding, C., Jiang, D., Zhao, Z., Li, Y., Ding, X., Gao, J., Zhou, H., Luo, C., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01231-4 · Cited by 183
Increased Oxidative Stress as a Selective Anticancer Therapy
Liu, J., & Wang, Z. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/294303 · Cited by 186
“Low to moderate levels of ROS are indispensable to normal cellular proliferation, differentiation, and survival [2].”
BackgroundInfluentialAhamed, M., Khan, M. A. M., Akhtar, M. J., Alhadlaq, H. A., & Alshamsan, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17559-9 · Cited by 185
Ju, H.-Q., Lu, Y.-X., Chen, D.-L., Zuo, Z.-X., Liu, Z.-X., Wu, Q.-N., Mo, H.-Y., Wang, Z.-X., Wang, D.-S., Pu, H.-Y., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy160 · Cited by 191
Self-citationDrug Resistance in Glioblastoma: The Two Faces of Oxidative Stress
Olivier, C., Oliver, L., Lalier, L., & Vallette, F. M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.620677 · Cited by 182
“An elevated activity of the latter enzymes and an increase in the level of reduced glutathione (GSH) are associated with the acquisition of resistance (Trachootham et al., 2009; Ortega et al., 2011).”
BackgroundSun, J., Zhou, C., Zhao, Y., Zhang, X., Chen, W., Zhou, Q., Hu, B., Gao, D., Raatz, L., Wang, Z., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101942 · Cited by 189
Stuart, S. D., Schauble, A., Gupta, S., Kennedy, A. D., Keppler, B. R., Bingham, P. M., & Zachar, Z. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-4 · Cited by 183
“To further explore the metabolic and cell death effects produced by CPI-613 treatment, we initially investigated production of ROS, which have emerged as regulatory effectors of both phenomena [31].”
Ge, W., Zhao, K., Wang, X., Li, H., Yu, M., He, M., Xue, X., Zhu, Y., Zhang, C., Cheng, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.008 · Cited by 188
“This expands our understanding of onco as chemotherapy and radiotherapy often utilize elevated ROS to remove cancers (Trachootham et al., 2009).”
BackgroundThe Hallmarks of Flavonoids in Cancer
Ponte, L. G. S., Pavan, I. C. B., Mancini, M. C. S., da Silva, L. G. S., Morelli, A. P., Severino, M. B., Bezerra, R. M. N., & Simabuco, F. M. (2021) · Molecules · doi:10.3390/molecules26072029 · Cited by 180
Gao, M., & Tang, B. Z. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.213076 · Cited by 187
Zhang, L., Wang, D., Yang, K., Sheng, D., Tan, B., Wang, Z., Ran, H., Yi, H., Zhong, Y., Lin, H., et al. (2018) · Advanced Science · doi:10.1002/advs.201800049 · Cited by 185
Ye, S., Hananya, N., Green, O., Chen, H., Zhao, A. Q., Shen, J., Shabat, D., & Yang, D. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005429 · Cited by 185
Yue, C., Zhang, C., Alfranca, G., Yang, Y., Jiang, X., Yang, Y., Pan, F., Fuente, J. M. D. L., & Cui, D. (2016) · Theranostics · doi:10.7150/thno.14101 · Cited by 184
“However, normal cells with lower basal stress and maintenance appear to have a higher capacity to fight against additional ROS-generating insults than cancer cells [13].”
Leanza, L., Romio, M., Becker, K. A., Azzolini, M., Trentin, L., Managò, A., Venturini, E., Zaccagnino, A., Mattarei, A., Carraretto, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.003 · Cited by 188
“…(Hockenb-ery, 2010); and (3) cancer cells are characterized by an altered redox state (e.g., Sabharwal and Schumacker, 2014) and molecules (such as our derivatives) able to increase oxidative stress above a critical threshold may selectively kill them (Ralph et al., 2010; Trachootham et al., 2009).”
Single Atom Catalysts Remodel Tumor Microenvironment for Augmented Sonodynamic Immunotherapy
Geng, B., Hu, J., He, X., Zhang, Z., Cai, J., Pan, D., & Shen, L. (2024) · Advanced Materials · doi:10.1002/adma.202313670 · Cited by 183
Small molecules regulating reactive oxygen species homeostasis for cancer therapy
Zhang, J., Duan, D., Song, Z., Liu, T., Hou, Y., & Fang, J. (2021) · Medicinal Research Reviews · doi:10.1002/med.21734 · Cited by 184
“tively prevent the early stages of tumorigenesis (Figure 3A).(14,18,117) The second strategy is to enhance the cellular ROS levels for cancer therapy by stimulating intracellular ROS levels to a toxicity threshold to activate ROS‐”
BackgroundYu, J., Zhao, F., Gao, W., Yang, X., Ju, Y., Zhao, L., Guo, W., Xie, J., Liang, X.-J., Tao, X., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b01740 · Cited by 183
Lin, L.-S., Wang, J.-F., Song, J., Liu, Y., Zhu, G., Dai, Y., Shen, Z., Tian, R., Song, J., Wang, Z., et al. (2019) · Theranostics · doi:10.7150/thno.39831 · Cited by 179
Nanoplatform-based cascade engineering for cancer therapy
Chen, J., Zhu, Y., Wu, C., & Shi, J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00607f · Cited by 182
Mitochondria as a target in treatment
Frantz, M., & Wipf, P. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20554 · Cited by 177
“Other redox-active anticancer candidates are at various stages of clinical development and have been reviewed previously (Engel and Evens 2006; Toogood 2008; Trachootham et al. 2009).”
BackgroundUltrasmall Alloy Nanozyme for Ultrasound- and Near-Infrared Light-Promoted Tumor Ablation
Jana, D., Wang, D., Bindra, A. K., Guo, Y., Liu, J., & Zhao, Y. (2021) · ACS Nano · doi:10.1021/acsnano.1c01830 · Cited by 183
A Metabolic Multistage Glutathione Depletion Used for Tumor-Specific Chemodynamic Therapy
Huang, Y., Wu, S., Zhang, L., Deng, Q., Ren, J., & Qu, X. (2022) · ACS Nano · doi:10.1021/acsnano.1c10231 · Cited by 181
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2106) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 177
“However, when ROS concentrations become extremely high, they lead to tumor cell death [7].”
BackgroundWang, L., Huo, M., Chen, Y., & Shi, J. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.018 · Cited by 181
Zhen, W., Liu, Y., Wang, W., Zhang, M., Hu, W., Jia, X., Wang, C., & Jiang, X. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201916142 · Cited by 181
Ahamad, M. S., Siddiqui, S., Jafri, A., Ahmad, S., Afzal, M., & Arshad, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110003 · Cited by 177
Deconvoluting the role of reactive oxygen species and autophagy in human diseases
Wen, X., Wu, J., Wang, F., Liu, B., Huang, C., & Wei, Y. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.013 · Cited by 178
Targeting Glutamine Metabolism and Redox State for Leukemia Therapy
Gregory, M. A., Nemkov, T., Park, H. J., Zaberezhnyy, V., Gehrke, S., Adane, B., Jordan, C. T., Hansen, K. C., D’Alessandro, A., & DeGregori, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3223 · Cited by 171
An, Q., Sun, C., Li, D., Xu, K., Guo, J., & Wang, C. (2013) · ACS Applied Materials & Interfaces · doi:10.1021/am4042367 · Cited by 177
Ma, S., Song, W., Xu, Y., Si, X., Lv, S., Zhang, Y., Tang, Z., & Chen, X. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b05265 · Cited by 178
Nanomaterials to relieve tumor hypoxia for enhanced photodynamic therapy
Zhang, C., Qin, W.-J., Bai, X.-F., & Zhang, X.-Z. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100960 · Cited by 180
Feng, S., Lu, J., Wang, K., Di, D., Shi, Z., Zhao, Q., & Wang, S. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134886 · Cited by 179
Qiao, C., Yang, J., Shen, Q., Liu, R., Li, Y., Shi, Y., Chen, J., Shen, Y., Xiao, Z., Weng, J., et al. (2018) · Advanced Materials · doi:10.1002/adma.201705054 · Cited by 178
Impact of ROS Generated by Chemical, Physical, and Plasma Techniques on Cancer Attenuation
Mitra, S., Nguyen, L. N., Akter, M., Park, G., Choi, E. H., & Kaushik, N. K. (2019) · Cancers · doi:10.3390/cancers11071030 · Cited by 174
“In the quest for a new warrior in the present state of cancer treatments, it is found that treatments targeting ROS by any new tool can promise a new and more successful era of cancer therapy [14].”
BackgroundInfluentialShin, D., Lee, J., You, J. H., Kim, D., & Roh, J.-L. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101418 · Cited by 178
Weng, M.-S., Chang, J.-H., Hung, W.-Y., Yang, Y.-C., & Chien, M.-H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0728-0 · Cited by 172
“Blockade of oxidative stress-mediated signaling pathways is a good strategy for cancer treatment and prevention [17, 18].”
BackgroundStrategies toward Organic Carbon Monoxide Prodrugs
Ji, X., & Wang, B. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00019 · Cited by 178
Sun, Q., Wang, Z., Liu, B., He, F., Gai, S., Yang, P., Yang, D., Li, C., & Lin, J. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214267 · Cited by 176
Duan, D., Zhang, B., Yao, J., Liu, Y., & Fang, J. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.02.016 · Cited by 174
Wan, Y., Lu, G., Wei, W.-C., Huang, Y.-H., Li, S., Chen, J.-X., Cui, X., Xiao, Y.-F., Li, X., Liu, Y., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c02767 · Cited by 175
Ma, Y., Ha, C. S., Hwang, S. W., Lee, H. J., Kim, G. C., Lee, K.-W., & Song, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091947 · Cited by 173
Yang, B., Chen, Y., & Shi, J. (2019) · Materials Science and Engineering: R: Reports · doi:10.1016/j.mser.2019.01.001 · Cited by 171
Metabolic rewiring in melanoma
Ratnikov, B. I., Scott, D. A., Osterman, A. L., Smith, J. W., & Ronai, Z. A. (2017) · Oncogene · doi:10.1038/onc.2016.198 · Cited by 171
Shen, W., Liu, W., Yang, H., Zhang, P., Xiao, C., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.011 · Cited by 176
“It is gener ally accepted that a moderate increase of ROS may promote cancer i itiation, progression and even generation of MDR, while excessive amounts of ROS can cause oxidative damage of biomolecules or overcome MDR in cancer [22].”
BackgroundRepurposing of auranofin: Thioredoxin reductase remains a primary target of the drug
Zhang, X., Selvaraju, K., Saei, A. A., D'Arcy, P., Zubarev, R. A., Arnér, E. S., & Linder, S. (2019) · Biochimie · doi:10.1016/j.biochi.2019.03.015 · Cited by 169
Wang, Q., Cheng, C., Zhao, S., Liu, Q., Zhang, Y., Liu, W., Zhao, X., Zhang, H., Pu, J., Zhang, S., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202201101 · Cited by 174
Antioxidative nanomaterials and biomedical applications
Liu, Y., & Shi, J. (2019) · Nano Today · doi:10.1016/j.nantod.2019.05.008 · Cited by 172
Stimuli responsive nanosonosensitizers for sonodynamic therapy
Jiang, Z., Xiao, W., & Fu, Q. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.003 · Cited by 173
Bianchi, G., Martella, R., Ravera, S., Marini, C., Capitanio, S., Orengo, A., Emionite, L., Lavarello, C., Amaro, A., Petretto, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3688 · Cited by 173
“The return of cancer cells to the normal respiratory mode maintained by normal cells could also promote cancer cell death if the respiration was accompanied by electron leakage and superoxide generation [12, 13], leading to cellular damage and apoptosis [14, 15].”
BackgroundThe gold complex auranofin: new perspectives for cancer therapy
Abdalbari, F. H., & Telleria, C. M. (2021) · Discover Oncology · doi:10.1007/s12672-021-00439-0 · Cited by 167
“The toxicity of the combination therapy was rescued by ROS scavengers, demonstrating once again the critical role of redox homeostasis to maintain the wellbeing of cancer cells that operate with dangerously high background levels of ROS [49].”
BackgroundHu, J., Jiang, W., Yuan, L., Duan, C., Yuan, Q., Long, Z., Lou, X., & Xia, F. (2021) · Aggregate · doi:10.1002/agt2.10 · Cited by 172
Dai, Y., Cheng, S., Wang, Z., Zhang, R., Yang, Z., Wang, J., Yung, B. C., Wang, Z., Jacobson, O., Xu, C., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b06852 · Cited by 172
Gong, X., Smith, J., Swanson, H., & Rubin, L. (2018) · Molecules · doi:10.3390/molecules23040905 · Cited by 172
“Increased cancer cell ROS production that is associated with targeted cancer killing [23] also sustains elevated cancer proliferative demands, in effect, driving tumor cells toward a redox stress threshold and increasing tumor susceptibility to ROS-modulating agents.”
BackgroundDeubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion
Harris, I. S., Endress, J. E., Coloff, J. L., Selfors, L. M., McBrayer, S. K., Rosenbluth, J. M., Takahashi, N., Dhakal, S., Koduri, V., Oser, M. G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.020 · Cited by 170
Wang, H., Wang, Z., Zhang, Z., Liu, J., & Li, H. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.05.013 · Cited by 184
Toward a new STATe: The role of STATs in mitochondrial function
Meier, J. A., & Larner, A. C. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.12.005 · Cited by 168
Dual targeting of the thioredoxin and glutathione systems in cancer and HIV
Benhar, M., Shytaj, I. L., Stamler, J. S., & Savarino, A. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85339 · Cited by 166
Zhang, J., Zhang, B., Li, X., Han, X., Liu, R., & Fang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21507 · Cited by 167
Wei, D., Yu, Y., Zhang, X., Wang, Y., Chen, H., Zhao, Y., Wang, F., Rong, G., Wang, W., Kang, X., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c06190 · Cited by 170
Fan, Z., Yang, G., Zhang, W., Liu, Q., Liu, G., Liu, P., Xu, L., Wang, J., Yan, Z., Han, H., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16957 · Cited by 166
Zhou, W., Jia, Y., Liu, Y., Chen, Y., & Zhao, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112346 · Cited by 178
“As a prominent feature of cancer, hypoxia significantly changes the ROS level in tumor tissues, so the ROS concentration in tumor cells (10−4 M) is much higher than that in normal tissues (2 × 10−8 M) [28,29].”
BackgroundLi, F., Han, X., Li, F., Wang, R., Wang, H., Gao, Y., Wang, X., Fang, Z., Zhang, W., Yao, S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.001 · Cited by 169
“Among several ROS-inducing agents (Raj et al., 2011; Trachootham et al., 2009), piperlongumine (PL) was most effective to promote apoptosis in LKB1-deficient cancer cell lines (Figures S7A and S7B).”
Effect of atmospheric gas plasmas on cancer cell signaling
Ishaq, M., Evans, M. (., & Ostrikov, K. (. (2014) · International Journal of Cancer · doi:10.1002/ijc.28323 · Cited by 168
“This process needs to be very selective so that normal, nontumor cells are minimally affected.(50) Cellular ROS levels are maintained at steady state by pro- and antioxidants.”
Background
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.